Cybin Inc CYBN:NYSE American

RT Quote | Last NYSE Arca, VOL From CTA | USD
after hours iconAfter Hours: Last | 05/03/24 EDT
0.35quote price arrow up+0.0035 (+1.00%)
Volume
37,204
Close
0.35UNCH (UNCH)
Volume
2,683,141
52 week range
0.21 - 0.74
Loading...
  • Open0.3526
  • Day High0.3589
  • Day Low0.3451
  • Prev Close0.35
  • 52 Week High0.74
  • 52 Week High Date10/31/23
  • 52 Week Low0.21
  • 52 Week Low Date06/06/23

Key Stats

  • Market Cap264.17M
  • Shares Out759.69M
  • 10 Day Average Volume2.67M
  • Dividend-
  • Dividend Yield-
  • Beta-
  • YTD % Change-14.63

KEY STATS

  • Open0.3526
  • Day High0.3589
  • Day Low0.3451
  • Prev Close0.35
  • 52 Week High0.74
  • 52 Week High Date10/31/23
  • 52 Week Low0.21
  • 52 Week Low Date06/06/23
  • Market Cap264.17M
  • Shares Out759.69M
  • 10 Day Average Volume2.67M
  • Dividend-
  • Dividend Yield-
  • Beta-
  • YTD % Change-14.63

RATIOS/PROFITABILITY

  • EPS (TTM)-0.21
  • P/E (TTM)-1.64
  • Fwd P/E (NTM)-
  • EBITDA (TTM)-
  • ROE (TTM)-
  • Revenue (TTM)-
  • Gross Margin (TTM)-
  • Net Margin (TTM)-
  • Debt To Equity (MRQ)-

EVENTS

  • Earnings Date06/24/2024(est)
  • Ex Div Date-
  • Div Amount-
  • Split Date-
  • Split Factor-

Latest On Cybin Inc

 

Profile

MORE
Cybin Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company creates psychedelic-based therapeutics to address the unmet need for treatment options for people who suffer from mental health conditions. Its N,N-dimethyltryptamine (DMT) and dDMT programs creates a dataset of systematic research on these psychedelic molecules. The Company is developing CYB003, a proprietary deuterated psilocybin analog for the treatment of major depressive disorder and...
Eric So
Executive Chairman of the Board, President, Co-founder
Douglas Drysdale
Chief Executive Officer
Greg Cavers
Chief Financial Officer
Address
100 King Street West, Suite 5600
Toronto, ON
M5X 1C9
Canada